NVDA

174.47

+5.58%↑

AVGO.US

309.48

+5.44%↑

ORCL

147.15

+6.18%↑

337.66

+4.72%↑

CSCO

77.63

+0.69%↑

NVDA

174.47

+5.58%↑

AVGO.US

309.48

+5.44%↑

ORCL

147.15

+6.18%↑

337.66

+4.72%↑

CSCO

77.63

+0.69%↑

NVDA

174.47

+5.58%↑

AVGO.US

309.48

+5.44%↑

ORCL

147.15

+6.18%↑

337.66

+4.72%↑

CSCO

77.63

+0.69%↑

NVDA

174.47

+5.58%↑

AVGO.US

309.48

+5.44%↑

ORCL

147.15

+6.18%↑

337.66

+4.72%↑

CSCO

77.63

+0.69%↑

NVDA

174.47

+5.58%↑

AVGO.US

309.48

+5.44%↑

ORCL

147.15

+6.18%↑

337.66

+4.72%↑

CSCO

77.63

+0.69%↑

Начало・Списък с акции・Clarivate PLC

Clarivate PLC

Отворен

СекторТехнологични

2.47 0.41

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

2.42

Максимум

2.6

Ключови измерители
By Trading Economics
Приходи	233M 204M
Продажби	-6.1M 617M
EPS	0.2
Марж на печалбата	33.096
Служители	12,000
EBITDA	-5.3M 231M

Препоръки
By TipRanks
Препоръки	Неутрален
12-месечна прогноза	+36.76% upside

Дивиденти
By Dow Jones
Следващи печалби	28.04.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	421M 1.6B
Предишно отваряне	2.06
Предишно затваряне	2.47

Настроения в новините

By Acuity

29%

71%

78 / 375 Класиране в Technology

Техническа оценка

By Trading Central

Увереност

Bullish Evidence

4.2845 / 4.395 Подкрепа & съпротива

Clarivate PLC Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

31.03.2026 г., 23:31 ч. UTC

Горещи акции

Stocks to Watch: Nike, RH, NCino

31.03.2026 г., 22:35 ч. UTC

Печалби

Nike Guides for Sales Declines Ahead as Turnaround Plan Hits Snags -- 2nd Update

1.04.2026 г., 00:00 ч. UTC

Придобивния, сливания и поглъщания

The Year Is Off to the Strongest Start for Big Deals Ever -- WSJ

31.03.2026 г., 23:50 ч. UTC

Придобивния, сливания и поглъщания

Nxera Pharma: Partner Centessa Pharmaceuticals to Be Acquired by Lilly >LLY 4565.TO

31.03.2026 г., 23:43 ч. UTC

Пазарно говорене

Nikkei May Rise on Hopes for Iran War Ending Soon -- Market Talk

31.03.2026 г., 23:33 ч. UTC

Пазарно говорене

Значими събития в новините

Gold Edges Higher on Signs of De-Escalating Middle East Tensions -- Market Talk

31.03.2026 г., 23:21 ч. UTC

Печалби

Nike Stock Slides on Tariff Impact Despite Earnings Beat; Turnaround Continues -- Barrons.com

31.03.2026 г., 23:14 ч. UTC

Пазарно говорене

Печалби

Nike CEO Says Turnaround is Taking Longer Than He'd Like -- Market Talk

31.03.2026 г., 23:12 ч. UTC

Пазарно говорене

Aurelia's Cash Flow Strength Highlighted by New Financing Deal -- Market Talk

31.03.2026 г., 22:36 ч. UTC

Печалби

China Vanke 2025 Loss Widens >000002.SZ

31.03.2026 г., 22:36 ч. UTC

Печалби

China Vanke: Increase in Inventory Impariment Provision Among Factors Weighing On Results>000002.SZ

31.03.2026 г., 22:36 ч. UTC

Печалби

China Vanke 2025 Loss CNY88.56B Vs. Loss CNY49.48B >000002.SZ

31.03.2026 г., 22:36 ч. UTC

Печалби

China Vanke: Will Take Time to Resolve Issues Caused by High Debt Levels>000002.SZ

31.03.2026 г., 22:36 ч. UTC

Печалби

China Vanke 2025 Rev CNY233.43B Vs. CNY343.18B >000002.SZ

31.03.2026 г., 21:46 ч. UTC

Придобивния, сливания и поглъщания

Big Drug Companies Hunting for Deals Are Lowering Their Sights -- WSJ

31.03.2026 г., 21:36 ч. UTC

Пазарно говорене

West African Resources's Costs Higher Than Bull Expected -- Market Talk

31.03.2026 г., 21:35 ч. UTC

Печалби

Nike Expects China Sales Down 20% in 4Q, CFO Says

31.03.2026 г., 21:35 ч. UTC

Печалби

Nike Expects Modest Growth in North America, Offset by Declines in China, Converse Brand in 4Q, CFO Says

31.03.2026 г., 21:35 ч. UTC

Печалби

Nike Forecasts 4Q Sales Down 2% to 4%, CFO Says

31.03.2026 г., 21:33 ч. UTC

Придобивния, сливания и поглъщания

Biotechs Are a Healthy Growth Bet Thanks to M&A and New Drugs -- Barrons.com

31.03.2026 г., 21:33 ч. UTC

Печалби

Nike Expects Sales Down Low-Single Digits From Now Through End of Calendar Year, CFO Says

31.03.2026 г., 21:32 ч. UTC

Печалби

Nike Expects 1Q to Be Final Quarter Where Tariffs Continue to Be Year-Over-Year Headwind to Margins, CFO Says

31.03.2026 г., 21:28 ч. UTC

Печалби

Nike Expects to End 4Q With Elevated Inventory, CFO Says

31.03.2026 г., 21:26 ч. UTC

Печалби

Nike Increasingly Confident It Will Return to Balanced Growth in North America in Direct, Wholesale Channels, CFO Says

31.03.2026 г., 21:25 ч. UTC

Печалби

Nike Expects Supply-Chain Changes to Pay Off Starting in Fiscal 2027, CFO Says

31.03.2026 г., 21:24 ч. UTC

Пазарно говорене

Печалби

Nike: Turnaround Plan Progressing at Different Rates -- Market Talk

31.03.2026 г., 21:22 ч. UTC

Печалби

Nike CFO Expects Football Training and Basketball Will Return to Growth Over Next Few Quarters

31.03.2026 г., 21:22 ч. UTC

Печалби

Nike's Sportswear Business Declined Low-Double Digits in 3Q, CFO Says

31.03.2026 г., 21:21 ч. UTC

Печалби

Nike's Digital Channel Still Too Promotional, CFO Says

31.03.2026 г., 21:20 ч. UTC

Печалби

Nike CEO: Converse Remains Important to Portfolio

Сравнение с други в отрасъла

Ценова промяна

Clarivate PLC Прогноза

Ценова цел

By TipRanks

36.76% нагоре

12-месечна прогноза

Среден 3.46 USD 36.76%

Висок 6 USD

Нисък 2.4 USD

Според 6 анализатори от Wall Street, предложили 12-месечна ценова цел за Clarivate PLC през последните три месеца.

Консенсусна оценка

By TipRanks

Неутрален

6 ratings

Купи

Задържане

Продай

Според 6 анализатори, дали борсови рейтинги на Clarivate PLC през последните 3 месеца.

Техническа оценка

By Trading Central

4.2845 / 4.395Подкрепа & съпротива

Recent bullish events outweigh bearish events.

There is one bullish event.

There are no events.

Настроение

By Acuity

78 / 375 Класиране в Технологични

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Clarivate PLC

Clarivate Plc operates as an information services provider in the Americas, the Middle East, Africa, Europe, and the Asia Pacific. It operates through three segments: Academia & Government, Life Sciences & Healthcare, and Intellectual Property. The company offers Web of Science and InCites, that analyzes and explores the academic research landscape and manages research information; ProQuest One and Ebook Central that provides comprehensive content collections to institutions in a cost-effective manner; and Alma and Polaris, that manages academic resources and services, connect users, and support research publications. It also provides Patent and Trademark Renewals, that supports paralegal and admin tasks throughout the patent and trademark protection and maintenance process; CompuMark and Derwent, that supports critical decisions around patent and trademark protection, risk, and value creation throughout the innovation and brand lifecycle; IPFolio and Foundation IP that creates a structured environment for the protection and management of global patent and trademark assets. In addition, the company offers Cortellis Competitive Intelligence and Cortellis Drug Discovery Intelligence, that supports the development of new drugs and medical devices from discovery to clinical trials; Cortellis Regulatory Intelligence and OFF-X to monitor drug safety issues and adhere to regulatory protocols; Real World Data and Optimize that inform commercial launch strategy and set pricing for optimal reimbursement. It serves corporations, universities, law firms, government agencies, public libraries, and other professional services organizations. The company was formerly known as Clarivate Analytics Plc and changed its name to Clarivate Plc in May 2020. Clarivate Plc was founded in 1864 and is headquartered in London, the United Kingdom.